board

 
 
about 05.27.2019 mc_101316022 copy square.jpg

Adam Gridley, MBA, Executive Chairman

Adam is currently President, CEO, and Director of Histogenics, a cell therapy and biologics company developing novel therapeutics for cartilage defects. He joined Histogenics in 2014 and completed a successful $70 million IPO, raised over $130 million, recruited a new management team, and helped lead several successful clinical and manufacturing initiatives for the Company’s Phase 3 trial of NeoCart. In addition, he completed licensing transactions with Intrexon, MEDINET (Japan), and most recently a reverse merger with Ocugen Inc. Prior to Histogenics, Adam was Senior Vice President, Technical Operations/Global Site Head at Merz Pharma, one of the world’s largest aesthetics companies. He was previously Senior Vice President of Corporate Development at BioForm Medical, where he played a key role in BioForm’s IPO, several acquisitions and product launches, and ultimately the sale of BioForm to Merz. Adam is on the Board of Directors of the Alliance for Regenerative Medicine (ARM), and the Board of Advisors for Life Science Cares, a nonprofit organization leveraging the collective impact of the Boston life sciences industry to address poverty in the Boston area. Adam holds a BS and MBA from the University of Denver.

 
about 05.27.2019 ReddyHeadshot.jpg

Sashank Reddy, MD, PhD, Founder, President

Sashank is Medical Director for Johns Hopkins Technology Ventures, recently appointed Assistant Professor of Plastic and Reconstructive Surgery and Biomedical Engineering at Johns Hopkins University, and a co-founder of LifeSprout. His current research efforts center on mechanisms of regeneration and homeostasis in skin and development of nanomaterials to support tissue regeneration and cell therapy. His discoveries have been published in leading journals including Nature, Cell, Cell Stem Cell and Science Translational Medicine. Sashank is also an accomplished entrepreneur and biomedical innovator. Earlier in his career he was at Third Rock Ventures where he served as a member of the founding team at Eleven Biotherapeutics (NASDAQ: SESN). In his role as Medical Director of Johns Hopkins Technology Ventures, Sashank advises faculty and University administration on enhancing the impact of discoveries through new company creation and corporate partnerships. Sashank received his undergraduate degree with University Honors from Johns Hopkins where he studied Biology and Humanistic Studies as one of the University’s Beneficial Hodson Scholars. He went on to complete MD and PhD studies at Harvard Medical School under the auspices of the NIH’s Medical Scientist Training Program.

 
about 06.18.2019 GOORNO eric B&W.jpg

Eric Goorno, MBA, Chief Executive Officer

Eric is the Chief Executive Officer of LifeSprout. He brings more than 25 years of operational experience in both early stage and high growth healthcare companies across multiple disease areas and medical specialties. Prior to joining LifeSprout, Eric had a long career with Boston Scientific, most recently as President of the firm’s $395 million Urology & Gynecology Division where he was responsible for establishing and driving the Division’s global strategy and sustained growth. Earlier at Boston Scientific Eric held positions as Vice President, New Market Development and Strategic Planning, Urology & Gynecology, Vice President of Operations, Microwave Divisions, and Vice President and General Manager, Symbiosis Division. After leaving Boston Scientific in 2009, he founded Pulse Veterinary Technologies, LLC where he served as Founder and CEO until the company’s successful acquisition. He then joined his next start up, BioDirection, as President and CEO before being recruited to the CEO position at LifeSprout. Earlier in his career Eric held various plant manager and operational roles at Synthes USA. Eric holds a BA from Tufts University, cum laude, in Political Science and an MBA from Harvard Business School.

 
about 06.07.2019 murren.jpg

Heather Murren, CFA

Heather is the co-founder of the Nevada Cancer Institute (NVCI) and served as its Chairman and Chief Executive from its founding in 2002 until June 2009. She remains a member of its board of directors. In 2009, United States Senate Majority Leader Harry Reid appointed her to the Financial Crisis Inquiry Commission. Heather served as a managing director, Global Securities Research and Economics, of Merrill Lynch where she was Group Head for the Global Consumer Products Equity Research effort. In 2004, she was recognized as one of the Influential Businesswoman of the Year by Las Vegas Magazine of the Las Vegas Review-Journal. She has received both Congressional recognition and commendation from the U.S. Senate for her work at Nevada Cancer Institute. In addition, she has received numerous awards for philanthropy. In 2006, she was cited as a Nevada Healthcare Hero by Nevada Business Journal. Ms. Murren is a graduate of the Johns Hopkins University and has served in the past as a member of the Board of Trustees of the Johns Hopkins University and co-chair of the University’s Rising to the Challenge Campaign which raised over $6 billion. She was also a member of the Johns Hopkins University Zanvyl Krieger School of Arts and Sciences Advisory Council and founder of the Jochebed Scholarship.

 
about g-h 06-13-2019.jpg

Gi-Hyeok Yang, PhD

Gi-Hyeok is Vice President and member of the Board of Directors at Medytox Inc, one of Korea’s largest specialty pharmaceutical companies with a market capitalization greater than $2 billion. Medytox focuses on the development and sales of aesthetic neurotoxins and fillers. Prior to becoming Vice President, he served as senior managing director and executive director at Medytox. In addition, Gi-Hyeok is on the board of the privately-held cell therapy company Seraxis. He completed post-doctoral fellowships at both Michigan State University and the Korea Research Institute of Bioscience and Biotechnology. Gi-Hyeok holds a PhD from the Korea Advanced Institute of Science and Technology (KAIST).